Abstract
Purpose:
To evaluate the efficacy of dexamethasone 0.7mg intravitreal implant in patients with chronic postoperative cystoid macular edema.
Methods:
Twelve patients’ charts were retrospectively reviewed. Inclusion criteria comprised patients with postoperative cystoid macular edema. The main outcome measures were best corrected visual acuity (BCVA) and mean central retinal thickness (CRT).
Results:
Patients mean age was 72.3 years. All patients were pseudophakic. Five patients were diabetic. Four patients had received a previous treatment with intravitreal ranimizumab. The mean BCVA before intravitreal dexamethasone was 0.6 logmar. It improved to 0.4 at month 1 and was 0,5 at month 3. The pre injection mean CRT was 582.5 µm. It improved to 310 µm at month 1 and was 341,5 µm at month 3. Five patients presented an elevated intraocular pressure during the follow up.
Conclusions:
Intravitreal dexamethasone improved visual acuity and macular thickness at month 1 and month 3 in patients with postoperative cystoid macular edema. However its beneficial effect seemed to decrease at month 3.
Keywords: 505 edema •
487 corticosteroids •
445 cataract